Biodistribution and Radiation Dosimetry of I-mIBG in Adult Patients with Neural Crest Tumours and Extrapolation to Paediatric Models

Overview

Journal EJNMMI Phys

Specialty Radiology

Date 2024 Jan 3

PMID 38167953

Authors

Alexandros Moraitis

Walter Jentzen

Gloria Reiter

Jochen Schmitz

Thorsten Dirk Poppel

Manuel Weber

Ken Herrmann

Wolfgang Peter Fendler

Pedro Fragoso Costa

Andreas Bockisch

David Kersting

Affiliations

Soon will be listed here.

Abstract

Aim: Positron emission tomography (PET) using I-mIBG has been established for imaging and pretherapeutic dosimetry. Here, we report the first systematic analysis of the biodistribution and radiation dosimetry of I-mIBG in patients with neural crest tumours and project the results to paediatric patient models.

Methods: Adult patients with neural crest tumours who underwent sequential I-mIBG PET were included in this retrospective single-center analysis. PET data were acquired 4, 24, 48, and/or 120 h after administration of a mean of 43 MBq I-mIBG. Whole-body counting and blood sampling were performed at 2, 4, 24, 48 and 120 h after administration. Absorbed organ dose and effective dose coefficients were estimated in OLINDA/EXM 2.2 according to the MIRD formalism. Extrapolation to paediatric models was performed based on mass-fraction scaling of the organ-specific residence times. Biodistribution data for adults were also projected to I-mIBG and I-mIBG.

Results: Twenty-one patients (11 females, 10 males) were evaluated. For adults, the organs exposed to the highest dose per unit administered activity were urinary bladder (1.54 ± 0.40 mGy/MBq), salivary glands (0.77 ± 0.28 mGy/MBq) and liver (0.65 ± 0.22 mGy/MBq). Mean effective dose coefficient for adults was 0.25 ± 0.04 mSv/MBq (male: 0.24 ± 0.03 mSv/MBq, female: 0.26 ± 0.06 mSv/MBq), and increased gradually to 0.29, 0.44, 0.69, 1.21, and 2.94 mSv/MBq for the 15-, 10-, 5-, 1-years-old, and newborn paediatric reference patients. Projected mean effective dose coefficients for I-mIBG and I-mIBG for adults were 0.014 ± 0.002 mSv/MBq and 0.18 ± 0.04 mSv/MBq, respectively.

Conclusion: PET-based derived radiation dosimetry data for I-mIBG from this study agreed well with historical projected data from ICRP 53. The effective dose coefficients presented here may aid in guidance for establishing weight-based activity administration protocols.

References

Bar-Sever Z, Biassoni L, Shulkin B, Kong G, Hofman M, Lopci E . Guidelines on nuclear medicine imaging in neuroblastoma. Eur J Nucl Med Mol Imaging. 2018; 45(11):2009-2024. DOI: 10.1007/s00259-018-4070-8. View

. Radiation dose to patients from radiopharmaceuticals (addendum 2 to ICRP publication 53). Ann ICRP. 2000; 28(3):1-126. DOI: 10.1016/s0146-6453(99)00006-8. View

Giammarile F, Chiti A, Lassmann M, Brans B, Flux G . EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy. Eur J Nucl Med Mol Imaging. 2008; 35(5):1039-47. DOI: 10.1007/s00259-008-0715-3. View

Sgouros G . Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med. 1993; 34(4):689-94. View

Kersting D, Moraitis A, Sraieb M, Zarrad F, Umutlu L, Rischpler C . Quantification performance of silicon photomultiplier-based PET for small F-, Ga- and I-avid lesions in the context of radionuclide therapy planning. Phys Med. 2023; 114:103149. DOI: 10.1016/j.ejmp.2023.103149. View

Jentzen W, Weise R, Kupferschlager J, Freudenberg L, Brandau W, Bares R . Iodine-124 PET dosimetry in differentiated thyroid cancer: recovery coefficient in 2D and 3D modes for PET(/CT) systems. Eur J Nucl Med Mol Imaging. 2007; 35(3):611-23. DOI: 10.1007/s00259-007-0554-7. View

Lopci E, Chiti A, Castellani M, Pepe G, Antunovic L, Fanti S . Matched pairs dosimetry: 124I/131I metaiodobenzylguanidine and 124I/131I and 86Y/90Y antibodies. Eur J Nucl Med Mol Imaging. 2011; 38 Suppl 1:S28-40. DOI: 10.1007/s00259-011-1772-6. View

Pearson T, Guthrie D, Simpson J, Chinn S, Barosi G, Ferrant A . Interpretation of measured red cell mass and plasma volume in adults: Expert Panel on Radionuclides of the International Council for Standardization in Haematology. Br J Haematol. 1995; 89(4):748-56. DOI: 10.1111/j.1365-2141.1995.tb08411.x. View

Spix C, Pastore G, Sankila R, Stiller C, Steliarova-Foucher E . Neuroblastoma incidence and survival in European children (1978-1997): report from the Automated Childhood Cancer Information System project. Eur J Cancer. 2006; 42(13):2081-91. DOI: 10.1016/j.ejca.2006.05.008. View

10.

Aboian M, Huang S, Hernandez-Pampaloni M, Hawkins R, VanBrocklin H, Huh Y . I-MIBG PET/CT to Monitor Metastatic Disease in Children with Relapsed Neuroblastoma. J Nucl Med. 2020; 62(1):43-47. PMC: 9364877. DOI: 10.2967/jnumed.120.243139. View

11.

Jentzen W, Balschuweit D, Schmitz J, Freudenberg L, Eising E, Hilbel T . The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using 124I PET(/CT) imaging. Eur J Nucl Med Mol Imaging. 2010; 37(12):2298-306. DOI: 10.1007/s00259-010-1532-z. View

12.

Wieland D, Wu J, Brown L, Mangner T, Swanson D, BEIERWALTES W . Radiolabeled adrenergi neuron-blocking agents: adrenomedullary imaging with [131I]iodobenzylguanidine. J Nucl Med. 1980; 21(4):349-53. View

13.

Beijst C, de Keizer B, Lam M, Janssens G, Tytgat G, W A M de Jong H . A phantom study: Should I-mIBG PET/CT replace I-mIBG SPECT/CT?. Med Phys. 2017; 44(5):1624-1631. DOI: 10.1002/mp.12202. View

14.

. The 2007 Recommendations of the International Commission on Radiological Protection. ICRP publication 103. Ann ICRP. 2007; 37(2-4):1-332. DOI: 10.1016/j.icrp.2007.10.003. View

15.

Stabin M . OLINDA/EXM 2-The Next-generation Personal Computer Software for Internal Dose Assessment in Nuclear Medicine. Health Phys. 2023; 124(5):397-406. DOI: 10.1097/HP.0000000000001682. View

16.

Hope T, Allen-Auerbach M, Bodei L, Calais J, Dahlbom M, Dunnwald L . SNMMI Procedure Standard/EANM Practice Guideline for SSTR PET: Imaging Neuroendocrine Tumors. J Nucl Med. 2023; 64(2):204-210. DOI: 10.2967/jnumed.122.264860. View

17.

Vik T, Pfluger T, Kadota R, Castel V, Tulchinsky M, Alonso Farto J . (123)I-mIBG scintigraphy in patients with known or suspected neuroblastoma: Results from a prospective multicenter trial. Pediatr Blood Cancer. 2009; 52(7):784-90. DOI: 10.1002/pbc.21932. View

18.

Huang S, Bolch W, Lee C, Van Brocklin H, Pampaloni M, Hawkins R . Patient-specific dosimetry using pretherapy [¹²⁴I]m-iodobenzylguanidine ([¹²⁴I]mIBG) dynamic PET/CT imaging before [¹³¹I]mIBG targeted radionuclide therapy for neuroblastoma. Mol Imaging Biol. 2014; 17(2):284-94. PMC: 4336853. DOI: 10.1007/s11307-014-0783-7. View

19.

. Basic anatomical and physiological data for use in radiological protection: reference values. A report of age- and gender-related differences in the anatomical and physiological characteristics of reference individuals. ICRP Publication 89. Ann ICRP. 2003; 32(3-4):5-265. View

20.

Shapiro B, Copp J, Sisson J, Eyre P, Wallis J, BEIERWALTES W . Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma: experience in 400 cases. J Nucl Med. 1985; 26(6):576-85. View